+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?

      Cancer treatment reviews

      Adult, adverse effects, administration & dosage, Taxoids, Remission Induction, Prospective Studies, Prodrugs, chemically induced, Neutropenia, Neoplasm Metastasis, Middle Aged, Humans, Follow-Up Studies, analogs & derivatives, Fluorouracil, Female, Diarrhea, Deoxycytidine, drug therapy, Breast Neoplasms, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Antimetabolites, Antineoplastic, Aged

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Antimetabolite-taxane combinations have been shown to be effective chemotherapy in patients with metastatic breast cancer (MBC). A multicentre phase III trial comparing gemcitabine-docetaxel with capecitabine-docetaxel in women with anthracycline pretreated MBC was carried out in several European countries. Its results were presented recently [1]. One-hundred and fifty-three patients were randomly assigned to receive docetaxel (75 mg/m2, day 1) plus gemcitabine (1000 mg/m2, days 1, 8) and 152 received docteaxel plus capecitabine (1250 mg/m2, bid days 1-14) every 3 weeks until disease progression. No difference in efficacy of the two treatment regimens was observed in terms of progression-free survival (35 weeks in both treatment arms), overall response rate (32% vs. 32%), time to treatment failure (19 vs. 18 weeks, respectively), or response duration (36 vs. 42 weeks). Drug-related toxicity, particularly hand-foot syndrome, mucositis and diarrhoea, was more frequent with capecitabine-docetaxel and there was a higher incidence of drug-related treatment withdrawals with this combination. Gemcitabine-docetaxel appeared to have a more favourable risk-benefit profile than capecitabine-docetaxel, and is an important new treatment option for women with anthracycline-pretreated MBC.

          Related collections

          Author and article information



          Comment on this article